

1 **Predicting Progression Free Survival after Systemic Therapy in Advanced** 2 **Head and Neck Cancer: Bayesian regression and Model development**

3 Paul R Barber^{‡1,2}, Fabian Flores-Borja^{‡*3}, Giovanna Alfano^{‡4}, Kenrick Ng^{‡1}, Gregory Weitsman⁴,
4 Luigi Dolcetti⁴, Rami Mustapha⁴, Felix Wong⁴, Jose M Vicencio^{1,4}, Myria Galazi¹, James W
5 Opzoomer⁵, James N Arnold⁵, Shahram Kordasti⁶, Jana Doyle⁷, Jon Greenberg⁷, Magnus T
6 Dillon⁸, Kevin J Harrington⁸, Martin D Forster¹, Anthony C C Coolen^{9,10}, and Tony Ng^{1,3,4†}.

7

- 8 1. UCL Cancer Institute, Paul O’Gorman Building, University College London, London, UK
- 9 2. Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King’s
10 College London, London, UK.
- 11 3. Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King’s
12 College London, London, UK.
- 13 4. Richard Dimpleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical
14 Sciences, King's College London, London, UK.
- 15 5. Tumor Immunology Group, School of Cancer & Pharmaceutical Sciences, King’s College
16 London, London, UK
- 17 6. Systems Cancer Immunology, School of Cancer & Pharmaceutical Sciences, King’s College
18 London, London, UK
- 19 7. Daichii Sankyo Incorporated, New Jersey, USA
- 20 8. The Institute of Cancer Research, London, UK
- 21 9. Institute for Mathematical and Molecular Biomedicine, King’s College London, UK
- 22 10. Saddle Point Science Ltd, London, UK

23

24 ‡ These authors contributed equally to this work.

25 * Current address: Centre for Immunobiology and Regenerative Medicine, Barts & The
26 London School of Medicine and Dentistry, Queen Mary University of London, London, UK

27 † To whom correspondence should be addressed:

28 **Prof. Tony Ng**

29 Tel no: +44 (0) 20 7848 8056 (KCL)

30 E-mail: tony.ng@kcl.ac.uk, t.ng@ucl.ac.uk

31

32 **Word Count:** 4833 words (excluding figure legends and references)

33 **Abstract:** 248 words

34 **Running Title:** Predicting PFS in Head and Neck Cancer

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49 **List of abbreviations:**

50	C1 or C2	Timepoint before cycle 1 or cycle 2 of treatment
51	C-index	Harrell's Concordance Index
52	CT	Computed Tomography
53	CyTOF	Mass Cytometry
54	ddPCR	Digital Droplet Polymerase Chain Reaction
55	DN	Double-Negative
56	EGFR	Epidermal Growth Factor Receptor
57	FLIM	Fluorescence Lifetime Imaging Microscopy
58	FRET	Förster Resonance Energy Transfer
59	HPV	Human Papilloma Virus
60	HNSCC	Head and Neck Squamous Cell Cancer
61	HR	Hazard Ratio
62	KM	Kaplan-Meier
63	LFC	Log Fold Change
64	miRNA	Micro-RNA
65	PBMC	Peripheral Blood Mononuclear Cells
66	PCR	Polymerase Chain Reaction
67	PFS	Progression Free Survival
68	Tregs	Regulatory T cells

69 **ABSTRACT**

70 **Background:**

71 Advanced Head and Neck Squamous Cell Cancer (HNSCC) is associated with a poor
72 prognosis, and biomarkers that predict response to treatment are highly desirable. The primary
73 aim was to predict Progression Free Survival (PFS) with a multivariate risk prediction model.

74 **Methods:**

75 Blood samples from 56 HNSCC patients were prospectively obtained within a Phase 2 clinical
76 trial (NCT02633800), before and after the first treatment cycle of platinum-based chemotherapy,
77 to identify biological covariates predictive of outcome. A total of 42 baseline covariates were
78 derived pre-treatment, which were combined with 29 covariates after one cycle of treatment.
79 These covariates were ranked and selected by Bayesian multivariate regression to form risk
80 scores to predict PFS, producing “baseline” and “combined” risk prediction models respectively.

81 **Results:**

82 The baseline model comprised of CD33+CD14+ monocytes, Double Negative B cells and age,
83 in a weighted risk signature which predicted PFS with a concordance index (C-index) of 0.661.
84 The combined model composed of baseline CD33+CD14+ monocytes, baseline Tregs, after-
85 treatment changes in CD8 effector memory T cells, CD8 Central memory T cells and CD3 T
86 Cells, along with the hypopharyngeal primary tumor subsite. This weighted risk signature
87 exhibited an improved C-index of 0.757. There was concordance between levels of
88 CD33+CD14+ myeloid cells in tumor tissue, as demonstrated by imaging mass cytometry, and
89 peripheral blood in the same patients. This monocyte subpopulation also had univariate
90 predictive value (log-rank p value = 0.03) but the C-index was inferior to the combined
91 signature.

92 **Conclusions:**

93 This immune-based combined multimodality signature, obtained through longitudinal peripheral
94 blood monitoring, presents a novel means of predicting response early on during the treatment
95 course.

96 **Funding:**

97 Daiichi Sankyo Inc, Cancer Research UK, EU IMI2 IMMUCAN, UK Medical Research
98 Council, European Research Council (335326), National Institute for Health Research and The
99 Institute of Cancer Research.

100

101

102

103 **INTRODUCTION**

104 Recurrent (R) or metastatic (M) Head and Neck Squamous Cell Carcinoma (HNSCC) is
105 associated with a poor prognosis. Until the KEYNOTE-048 study was published in 2019(1), the
106 standard-of-care, first line systemic treatment was the EXTREME regimen, consisting of a
107 platinum-based chemotherapy regimen and cetuximab, an anti-EGFR monoclonal antibody(2).
108 Even now, for patients with programmed death ligand 1 (PD-L1) negative tumors or those with
109 contraindications to the use of anti-PD1 immunotherapy, the EXTREME regimen remains a first
110 line standard-of-care.

111 While effective, this regimen is associated with toxicities. One of the key challenges for the
112 treating physician is to identify the patients who would benefit from this treatment regimen. A
113 predictive biomarker signature for patients with advanced HNSCC will help individualize
114 discussions with patients regarding the risk-benefit balance of this treatment regimen and may
115 guide patients who are likely to perform poorly towards alternative therapy regimens or clinical
116 trials.

117 The absence of predictive biomarkers in this patient cohort represents a significant clinical
118 unmet need. Until the development of PD-L1 as a biomarker for immunotherapy, efforts to
119 generate biomarkers in HNSCC have focused on gene-expression profiles, which are
120 dependent on the availability of tumor tissue and are only performed on pre-treatment
121 samples(3, 4). Signatures based on a single biological modality and taken at a single timepoint
122 may be insufficient to predict outcomes, as response to therapy relies on a dynamic interplay
123 between cancer genomics, immune profile, tumor microenvironment, and clinicopathological
124 characteristics of the patient receiving treatment(5, 6).

125 Efforts to develop a machine learning model to stratify survival risk by combining genetic
126 and clinicopathological characteristics have revealed some success in advanced oral squamous
127 cell carcinoma(7). We hypothesize that a multimodal analysis, taking into account both
128 clinicopathological and laboratory-based biological covariates at different timepoints, would
129 provide better predictive value.

130 We prospectively collected peripheral blood samples from a Phase 2 trial in R/M HNSCC
131 (NTC02633800)(8), which utilized a modified EXTREME regimen as a backbone, and
132 conducted a parallel exploratory analysis with the aim of generating a biomarker signature
133 which would predict outcomes to treatment. We hypothesized that the detailed definition of a
134 broad immune cell signature could contribute to the development of assays employing liquid
135 biopsies to predict clinical outcomes. We also incorporated the analysis of two circulating
136 microRNAs (miRNAs); miR-21-5p and miR-142-3p, which have previously demonstrated
137 prognostic and predictive utility(9, 10). As the trial investigated the efficacy of an anti-ErbB3
138 antibody, patritumab, administered alongside an anti-EGFR antibody, we simultaneously
139 analyzed EGFR-ErbB3 dimerization using Förster Resonance Energy Transfer (FRET) and
140 included it in our analysis.

141 By extracting information from patient samples at baseline and after the first cycle of
142 treatment within this trial, we aimed to develop a multimodal predictive signature for the
143 EXTREME regimen based on a novel Bayesian multivariate model. This can serve as a non-
144 invasive risk stratification for patients with R/M HNSCC using only peripheral blood, guiding the
145 clinician towards the likelihood of success early during the treatment course.

146

147 **MATERIALS AND METHODS**

148 **Study Design**

149 The clinical study design of the Phase 2 study (NCT02633800) and its associated
150 exploratory analysis are shown in Figure 1A. 87 patients were enrolled in the clinical trial.
151 Peripheral blood samples were collected before initiation of treatment (C1) and immediately
152 before the second cycle of treatment (C2). 31 patients were excluded due to incomplete paired
153 biological datasets, leaving 56 patients for analysis. Amongst these patients, there was no
154 difference in PFS as demonstrated by Kaplan-Meier survival curve analysis (Supplementary
155 Figure 1) regardless of whether the patients received patritumab, which reflected the results
156 published in the clinical trial. The baseline clinical characteristics of these 56 patients are shown
157 in Supplementary Table 1.


158 PBMC samples were analyzed using Flow Cytometry to generate unique immunological
159 subpopulations. Exosomes were extracted from the serum and analyzed for EGFR-ErbB3
160 dimerization and miRNA-21-5p and miRNA-142-3p (Figure 1B). These analyses yielded a total
161 of 29 unique biological covariates. Each covariate was obtained in pairs (C1 and C2),
162 generating a total of 58 laboratory-based covariates for the multivariate analysis (Figure 1B). To
163 mitigate individual baseline variations between patients, we evaluated changes between C1 and

164 C2 (in the form of log-fold change, LFC, of the variable of interest) instead of absolute values of
165 those parameters. A list of the laboratory-based and clinical covariates is provided in
166 Supplementary Table 2.

167 The baseline clinical characteristics, as well as value of the laboratory-based covariates at
168 baseline and after one cycle of treatment, did not significantly differ between the placebo and
169 patritumab cohorts (Supplementary Table 3). Therefore, in this exploratory analysis, samples
170 from both the control and investigational arms were analyzed together. The effect of adding the
171 investigational product, patritumab on Progression-Free Survival (PFS) was evaluated by
172 including it as an independent clinical covariate, denoted as 'Drug', in our multivariate analysis.

173 Written informed consent was obtained. Approval was obtained from ethics committees
174 (Research Ethics Committee reference: 15/LO/1670).

175



176

177

178 **Figure 1: Peripheral blood samples from the clinical trial were prospectively analyzed using a**

179 **multimodality platform (A) Schematic of clinical trial design and timepoints at which peripheral blood was obtained.**

180 (B) Fifty-six (n=56) paired blood samples, obtained pre-treatment (C1) and after one cycle of treatment (C2) were

181 subjected to Flow Cytometry, FRET-FLIM imaging and ddPCR analysis.

182

183 **Statistical Analysis**

184 To examine whether the various features and distribution of survival indices indicated
185 different prognostic outcomes, we built a model for predicting Progression-Free Survival (PFS).
186 Covariates were ranked by importance and selected by Bayesian multivariate proportional
187 hazards regression with backward elimination(11). We derived two models using separate
188 datasets: firstly, a baseline predictive model containing a dataset of 42 baseline covariates (29
189 laboratory parameters at baseline, C1, and 13 clinical characteristics). The second, a combined
190 predictive model, consists of 71 covariates, i.e. the 42 baseline covariates and a further 29
191 derived from the change in lab-based parameters between C1 and C2, measured by log fold
192 change (LFC) of the variable of interest.

193 The relative efficiency of the predictive model was assessed by using C-index (a metric
194 proposed by Harrell(12) to evaluate the accuracy of predictions made by an algorithm) and rank
195 correlation of the signature-generated risk scores with survival time. The number of significant
196 covariates in each prediction signature was determined with the aim of avoiding overfitting of the
197 signature to the study data using the “batch regression” option of the Saddle Point Signature
198 software (Saddle Point Science Ltd., London, UK), according to methods that were previously
199 published(13, 14). This is particularly important with small number of patients where an
200 independent test set is not possible. Systematic iterative covariate rejection and cross-validation
201 (5000 iterations) allowed for the selection of an optimal covariate set to avoid overfitting though
202 inclusion of too many covariates. The optimal set can be chosen in two ways, either based on
203 the peak prediction performance of cross-validation, or the more stringent method that equally
204 penalizes validation performance and overfitting (defined as the deviation between training and
205 validation performance). All signatures presented were chosen using the more stringent criterion
206 and data for all covariates is also presented for the purposes of identifying covariates that may

207 be important but do not quite meet the criterion. The regression included covariates
208 representing the missingness of data to account for the possibility that patient or sample
209 selection/rejection (for any reason) is biased with respect to outcome and therefore could be
210 informative. The missing data was imputed with the mean for that covariate. The importance
211 and significance of covariates can be judged by their assigned beta value (β) in the proportional
212 hazards model, and corresponding hazard ratio (HR) equal to $e^{2\beta}$. A negative beta value reflects
213 a lower risk of developing an event. The Signature software additionally judges the performance
214 of similar randomized data, which most often has beta values around zero and within a critical
215 range, such that any real covariate that has a beta value outside this critical range can be
216 judged to be performing significantly better than randomized data. This adds additional
217 confidence in the absence of an independent validation test set.

218 **Flow Cytometry**

219 Frozen PBMC samples were thawed and stained with Fixable viability dye (Yellow
220 Live/Dead™, Fisher Scientific) followed by two different panels of membrane markers. A panel
221 for T cells included CD3, CD4, CD8, CD25, CD45RO, CD127, CCR7, and HLA-DR. A panel for
222 B cells and monocytes included CD3, CD19, CD24, CD38, CD27, IgD, CD33, CD11b, CD14
223 and CD16 (full list of both antibody panels in Supplementary Table 4). These two panels allow
224 definition of immune cell populations as described in Supplementary Figure 2. Patients' samples
225 and corresponding Fluorescence Minus One (FMO) Controls were acquired in a Fortessa II flow
226 cytometer (BD, Berkshire, UK) and analyzed with FlowJo software (Tree Star). Populations
227 were quantified as proportions of their respective parent population.

228 **Isolation of Serum exosomes**

229 Exosomes were prepared using an optimized centrifugation method(15). Diluted serum
230 was centrifuged at 300xg for 10 min to remove cell debris, 5000xg for 20 min to remove large
231 vesicles and membrane fragments, and 12,200xg for 30 min to deplete microvesicles. This was
232 followed by 100,000xg ultracentrifugation for 120 min at 4 °C to pellet exosomes with a TLA-55
233 rotor (Beckman Coulter). After a second 100,000xg ultracentrifugation for 60 minutes, the
234 resulting pellets were washed and resuspended in PBS. Purified exosomal fractions were
235 diluted and used for nanoparticle tracking analysis (NTA) using a Nanosight LM-14 system.

236 **RNA Extraction and miRNA Expression Analysis**

237 RNA from cancer patients' serum exosomes was extracted using the TRIzol™ Plus
238 RNA Purification Kit (Thermo Fisher, UK) according to the manufacturer' instructions.
239 Quantification of gene expression in circulating exosomes was performed by ddPCR (Bio-Rad
240 QX100 system). Normalization of the RNA, between cycle 1 and cycle 2 therapy of each patient,
241 was performed using the expression levels of the housekeeping gene 18S (Assay ID,
242 Hs99999901_s1). For each sample, equal volume of RNA was used as template and cDNA
243 synthesis performed using the SuperScript® VILO™ MasterMix (Thermo Fisher, UK) according
244 to the manufacturer' instructions. MicroRNAs were reverse-transcribed individually using the
245 TaqMan™ MicroRNA Reverse Transcription Kit (Thermo Fisher, UK). For each sample,
246 the normalized amount of RNA was reverse transcribed in a 15 µl reaction using the standard
247 protocol and primers specific for each miRNA: miR-21-5p (assay ID, 000397), miR-142-3p
248 (assay ID, 000464). Then 7.5 µl of cDNA was added to a 20 µl reaction containing 12.5 µl 2X
249 ddPCR Supermix for Probes (Bio-Rad) and 1 µl 20X TaqMan miRNA PCR primer probe set;
250 each reaction was carried out in duplicate. Thermo cycling conditions were as it follows: 95 °C
251 for 10 min, then 50 cycles of 95 °C for 10 sec and 61 °C for 30 sec and a final inactivation step
252 at 98 °C for 12 min. PCR products were analyzed using the QuantaSoft™ Software (Bio-Rad).

253 **ErbB3-EGFR Dimer Quantification in Exosomes**

254 Exosomes were imaged on an 'Open' Fluorescence Lifetime Imaging Microscopy (FLIM)
255 system (16). Analysis was performed with the TRI2 software (v2.7.8.9, CRUK/MRC Oxford
256 Institute for Radiation Oncology, Oxford) as described previously (17, 18). Interfering effects of
257 autofluorescence were minimized with a lifetime filtering algorithm and the FRET efficiency
258 value for each patient calculated by: $FRET=1-\frac{\tau_{DA}}{\tau_D}$, where τ_D and τ_{DA} are the average lifetime of
259 Alexa Fluor546 in the matching donor (D) and donor-acceptor (DA) images.

260

261 **Imaging Mass Cytometry**

262 FFPE histological slides were stained with a panel of metal conjugated antibodies (full list of
263 antibodies listed in Supplementary Table 5).

264 In brief, antigen retrieval was performed on a Ventana Bench Mark Ultra with CC1 buffer
265 (Roche, 950-224). Slides were blocked for 1 hour at RT in 5% BSA, 5mg/ml human IgG in PBS
266 and stained overnight at 4°C in 4% BSA, PBS. DNA counterstain was performed with Iridium
267 (Fluidigm, 201192B) 125nM in PBS for 30 minutes at room temperature.

268 Ablation and data acquisition were performed on a Fluidigm Hyperion located within our
269 Biomedical Research Centre. Imaging analysis was performed using the RUNIMC R package:
270 RandomForest for classification and regression, Raster and SF for image manipulation and
271 segmentation (see <https://www.biorxiv.org/content/10.1101/2021.09.14.460258v1>, with code
272 available here: <https://github.com/luigidolcetti/RUNIMC>).

273 **RESULTS**

274 **The Model with Baseline Covariates Reveal Immune Subpopulations and Age Predict**


275 **PFS**

276 Bayesian multivariate proportional hazards regression was performed on the 42
277 covariates derived at baseline (C1) and PFS outcome. We utilized the stringent selection criteria
278 based on a proportional hazards regression model to minimize overfitting based on the cross-
279 validation performance (Figure 2A). This revealed two baseline immune subpopulations with a
280 beta value which exceeded the critical beta-value threshold, ie CD14+CD16+CD33+CD11b+
281 monocytes (thereafter referred to as CD33+CD14+ monocytes according to previous
282 nomenclature(19)) and double negative (CD27-IgD-) B cells (DN B cells), as well as one clinical
283 covariate – age (Figure 2B). Missingness covariates were included in this analysis and did not
284 affect the outcome of the signature.

285 Evaluation of the individual beta values reveal that baseline CD33+CD14+ monocytes
286 and double negative B cells have a beta, β value of -1.05 and -0.53 respectively, and hence a
287 higher baseline value of both populations is predictive of better PFS. Age, with a β value of 0.47,
288 is associated with poorer PFS. The hazard ratios (HR) of the individual covariates are depicted
289 in Figure 2C.

290 The risk scores generated from this signature were split at the median value to generate
291 low-risk and high-risk cohorts (Figure 2D). The median overall survival of the low-risk and high-
292 risk cohorts in this baseline predictive signature are 8.3 and 3.6 months respectively (log rank p-
293 value = 6.0 e-5) with a rank correlation of -0.29. The C-index of the predictive signature based
294 completely on baseline parameters is 0.661. The risk score equation is given in Supplementary
295 Figure 4.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



296

297 **Figure 2 High baseline CD33+CD14+ monocytes and Double Negative B cells Predict Overall Survival**

298 Covariates were ranked for importance and selected by a proportional hazards regression model with cross-validation and backward
 299 elimination. (A) Signature performance (defined as the classifier accuracy for predicting patient survival < or > median) as a function
 300 of the number of active covariates as covariates are eliminated based on cross validation performance. (B) Heatmap of covariate
 301 strength (beta value in the proportional hazards model) for the active covariates. Covariate elimination revealed three covariates in
 302 the optimal signature – CD33+CD14+ monocytes, Double Negative B Cells, and Age. (C) Forest plot of the three covariates within
 303 Progression Free Survival risk score with dotted line indicating the range, around 1, of typical random covariates. (D) Progression
 304 Free Survival Risk Signature Performance, low risk score (n=27) and high risk score (n=26). Log rank P-value = 6.0 e-5, with
 305 numbers at risk demonstrated under Kaplan-Meier curve. The multivariate analysis resulted in risk signatures that are linear
 306 combinations of weighted covariates. Their ability to predict outcome is demonstrated with data split by signature value.

307

308

309

310


311 **Incorporating laboratory-based covariates after one cycle of treatment improves ability to**
312 **predict PFS benefit**

313 We subsequently evaluated if the incorporation of early laboratory-based changes into the
314 signature improves its predictive ability. A separate predictive model incorporating 29 new
315 covariates, ie changes in laboratory-based parameters between cycle 1 and cycle 2 was
316 generated.

317 As before, we used a proportional hazards regression to determine a set of variables which
318 predict PFS. A total of six covariates were identified – three immune subpopulations with
319 negative beta values and hence are associated with better survival, ie baseline CD33+CD14+
320 monocytes, baseline CD4 memory regulatory T cells (HLA-DR⁻CD45RO⁺Tregs) and an increase
321 in CD8 effector memory T cells (CD45RO⁺CCR7⁻). An increase in two subpopulations, CD8
322 Central Memory T Cells (CD45RO⁺CCR7⁺) and CD3 T cells, was associated with inferior PFS.
323 The hypopharyngeal primary tumor site was also associated with a poorer PFS (Figure 3A and
324 B).

325 A multivariate analysis employing linear combinations of these six weighted covariates
326 generated a risk signature. Their ability to predict outcome is demonstrated with data split by
327 risk score, shown in Figure 3C. In this combined predictive signature, the median overall
328 survival of the low-risk and high-risk cohorts are 6.8 and 3.6 months respectively (log rank p-
329 value 0.004) with a rank correlation of -0.38 (Figure D). The C-index of the predictive signature,
330 which incorporates baseline variables with changes in laboratory parameters after one cycle of
331 treatment, is 0.757. Both values are greater in the combined signature when compared to the
332 signature which only accounts for baseline values. The risk score equation is given in
333 Supplementary Figure 4.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



334

335 **Figure 3 Model Incorporating Laboratory Changes After One Cycle of Treatment Exhibit Improved Predictive Value (A)**

336 Heatmap of covariate strength (beta value in the proportional hazards model) for the active covariates. Proportional hazards

337 regression revealed five immune subpopulations in the optimal model – Baseline CD33+CD14+ monocytes, Baseline CD4 Memory

338 Regulatory T Cells, LFC of CD8 effector memory T cells, LFC of CD8 central memory T cells and LFC of CD3 T cells. The primary

339 tumor site of hypopharynx also featured in the signature. A negative beta value is associated with lower risk score and hence better

340 progression free survival. LFC = Log Fold Change (B) Forest plot of the three covariates within Progression Free Survival risk score

341 (C) Progression Free Survival Risk Signature Performance, low risk score (n=29) and high risk score (n=24). Log rank P-value =

342 0.004, with numbers at risk demonstrated under Kaplan-Meier curve.

343


344

345 **EGFR-ErbB3 FRET may contribute to predictive signature**

346 While the combined predictive signature comprised predominantly of immunological
347 parameters, there is a suggestion that FRET difference may carry a degree of predictive value.
348 In Figure 3A (4th covariate from the bottom), the difference in EGFR-ErbB3 FRET (FRET.delta)
349 was associated with a negative beta value which suggests a better PFS. However, the
350 stringency that we have applied to optimal covariate selection means that this covariate fell
351 marginally short of featuring in the eventual predictive signature. Nonetheless, this is the first
352 time that this assay has been used within the context of a randomized controlled trial in
353 exosomes and the suggested predictive value of the dimer warrants some discussion.

354 Figure 4A displays intensity images and donor lifetime map of exosomes labelled with anti-
355 EGFR and anti-ErbB3 antibodies, along with an accompanying schematic (Figure 4B).

356 By dividing the patients with available FRET values by the median FRET.delta (n=43), there
357 was a suggestion that patients with a high FRET.delta exhibited a better PFS than patients with
358 a low FRET.delta. This difference was not statistically significant (p=0.2), and the predictive
359 capacity of this univariate is limited (Rank Correlation = -0.132, C-index = 0.561, Figure 4C).
360 Nonetheless, these results suggest a trend within a small patient cohort and can be explored in
361 future prospective studies.



362

363 **Figure 4 FRET/FLIM fluorescence assay of circulating exosomes extracted from patients** (A) Time-resolved fluorescence
 364 intensity images and donor lifetime map of exosomes labelled with Anti-EGFR-IgG-Alexa 546 and Anti-ErbB3-IgG-Cy5 extracellular
 365 antibodies (B) Schematic illustration of the fluorescent labelling geometry on exosomes and distance dependence of FRET
 366 efficiency (C) Progression Free Survival of subpopulations divided by median FRET difference, FRET.delta low (n=21) and
 367 FRET.delta high (n=22). Log rank P-value = 0.2, with numbers at risk demonstrated under Kaplan-Meier curve.

368


369 **Imaging Mass Cytometry of Tissue Reveals Correlation of CD33+CD14+ Myeloid Cell**
 370 **Subpopulation Between Tissue and Peripheral Blood**

371 Having established that immune subsets in peripheral blood predict therapeutic response within
372 a multivariate signature, we subsequently explored the relationship between the immune
373 findings in peripheral blood with tumor infiltrating leukocytes (TILs). We obtained sufficient
374 tissue from the biopsy at trial enrolment for in-depth profiling by imaging mass cytometry from
375 four patients.

376 Standard FFPE samples from these four patients were processed as described previously, and
377 the results clustered in an unsupervised fashion. The range of PFS for these patients was
378 between 1.6-11.2 months (Figure 5A). Representative images of nuclear staining, overlaid with
379 pixel-level classification, are shown for the four patients in Figure 5B. Heatmaps representing
380 the distribution of cell phenotypes for each patient, as expressed by a two-phase classification
381 conducted at pixel and cell level, are illustrated in Figure 5C. The list of cell populations
382 characterized by imaging mass cytometry, alongside their detailed signature, is shown in
383 Supplementary Table 6.

384 A total of 7 cell clusters identified on tissue mass cytometry were significantly different between
385 the four patients. CD33+CD14+ monocytes (cluster B-37) which featured in both baseline and
386 combined signatures, exhibited a diminishing trend of abundance across patients 1 to 4. Having
387 observed this trend, we subsequently correlated the levels of this population in tissue with
388 blood. The proportion of CD33+CD14+ monocytes in the blood was 17.4%, 5.39%, 2.0% and
389 2.47% for patients 1-4 respectively, suggesting a meaningful concordance between the levels of
390 this subpopulation in the patient tissue and peripheral blood.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



391

392

393


394 **Figure 5 Image Mass Cytometry of Four Patient Samples Using a 29 Marker Panel Analysis** (A) Waterfall plot of
395 Progression Free Survival showing the four patients used for imaging mass cytometry analysis (B) Representative
396 image of the nuclear staining overlaid with pixel-level classification (C) Heatmaps representing the distribution of cell
397 phenotypes for each patient, as expressed by a two-phase clustering conducted at pixel level (columns) and at cell
398 level (rows). Data represent row-normalized areas. Red tiles, which represent hot spots of classification concordance,
399 are further described in panel D (D) Differential analysis of the classification hotspots presented in panel C,
400 highlighting cell populations which were significantly different between patients. Data are presented as sum of areas
401 of positive cells normalized to the total area of the ROI and expressed as μm^2 (x1000) per mm^2 . Statistics: *adj-
402 $p < 0.05$, **adj- $p < 0.01$, ****adj- $p < 0.001$, Pairwise Wilcoxon Rank Sum Tests with Benjamini correction, $n \geq 3$.

403 **CD33+CD14+ Monocyte Population have high HLA-DR expression and univariate** 404 **predictive value**

405 Due to the consistency with which the CD33+CD14+ monocyte population appeared across our
406 study, we wanted to further characterize this population to determine its phenotype. During the
407 process of drafting this manuscript, our lab was concurrently processing PBMCs from a cohort
408 of patients at risk of developing lung cancer. Using a second flow cytometry staining panel
409 which incorporates an alternative set of markers on these samples, we further characterized this
410 monocyte subpopulation, affirming that these CD14+CD16+CD33+CD11b monocytes also
411 express high levels of HLA-DR and CD11c (Supplementary Figure 3). This affirms that our
412 population of interest closely resembles the previously described CD33+CD14+ monocytes(19).

413 MiRNA signatures have been implicated as a useful classifier for myeloid cell subsets(20). By
414 correlating the miRNA changes in our study with this monocytic subpopulation, a significant
415 correlation was identified between the log fold changes of miR-21-5p with the corresponding log
416 fold changes of CD33+CD14+ monocytes (Pearson's $r = 0.4343$, $p = 0.02092$, Figure 6A). We also
417 investigated the potential of baseline CD33+CD14+ monocyte levels at predicting PFS. Figure
418 6B illustrates a Kaplan-Meier curve of PFS by median CD33+CD14+ monocyte level, generating

419 a modest split which surpassed conventional statistical significance (log rank p-value = 0.03.
 420 However, the predictive capacity of CD33+CD14+ monocytes as a covariate was limited (C-
 421 index 0.593, rank-correlation 0.22). These values were inferior in predictive capacity compared
 422 to the baseline signature, which employed three covariates, and the combined predictive
 423 signature which employed six covariates (Figure 6C).



C

Covariates	Number of Covariates	Concordance Index	Magnitude of Rank Correlation	Log Rank
CD33+ Monocytes	1	0.593	0.22	0.03
Baseline Signature	3	0.661	0.29	6e-05
Combined Signature	6	0.757	0.40	0.004

424

425 **Figure 6 CD33+CD14+ Monocytes have some predictive value but predictive ability of signature is maximized with**
 426 **longitudinal sampling of peripheral blood** (A) (B) Correlation between miRNA 21 fold change and CD33+ monocyte fold change
 427 after one cycle of treatment. Correlation efficient of 0.4343, p value 0.02092. miR21: microRNA-21-5p, lfc: log-fold change (B)
 428 Kaplan-Meier Curve of PFS split by median CD33+CD14+ value, log rank p-value 0.03 (C) Table summarises C-index, rank
 429 correlation and log-rank p value based on type and number of covariates. There is an increasing C-index and rank correlation upon
 430 the strict selection of additional covariates into the predictive signature, with the strongest signature incorporating six covariates
 431 combining values from baseline and after one cycle of treatment.

432 **DISCUSSION**

433 There is a clinical unmet need to identify predictive biomarkers for treatment in head and
434 neck cancer. Gene expression profiling has revealed promising initial results in this domain but
435 have been limited to HPV positive HNSCC, which inherently have better prognoses. Recent
436 developments in the field of immunotherapy in HNSCC have focused on tissue-based
437 biomarkers, such as PD-L1, but when used in isolation these have not been sufficiently
438 predictive at identifying patients who would benefit(1).

439 While uni-modal biomarkers may offer some predictive value, the biology of HNSCC and
440 likelihood of response to treatment is likely to be dictated by an interplay between tumor
441 immunity, genomic signatures and a host of clinicopathological characteristics. There is an
442 increased interest in peripheral blood biopsies in recent years, particularly in the context of
443 peripheral blood mononuclear cells(21). The use of peripheral blood in deriving biomarkers
444 mitigates a few limitations posed by tissue biopsies – particularly the accessibility and amount of
445 tissue required. The ease of obtaining liquid biopsies also facilitates longitudinal monitoring of
446 response to treatment.

447 To our knowledge, ours is the first piece of work integrating multiple biological covariates
448 derived from peripheral blood to generate a signature which predicts treatment response. We
449 also demonstrate the effectiveness of sequential monitoring of peripheral blood variables and
450 the advantage of longitudinal monitoring at enhancing prediction of response, as shown by the
451 combined predictive signature. By employing cross validation iterations to estimate training and
452 validation errors, implementing advanced overfitting correlation protocols, using built-in
453 corrections for informative data missingness, and probabilistic covariate removal, we were able
454 to derive a robust optimal covariate set which correlates with PFS. This combination of analyses
455 has been shown to produce robust signatures that do generalize to unseen data(13).

456 The biological components of the predicted model warrant discussion. The only clinical
457 covariate to feature in the combined risk signature is the hypopharyngeal SCC sub-site, which
458 was adversely correlated with PFS. This corroborates previous findings that the 5-year relative
459 survival of patients with hypopharyngeal SCC is consistently the worst amongst different
460 anatomical HNSCC sub-sites (22, 23). The propensity of hypopharyngeal tumors to present at
461 the *de novo* advanced stage(24) and the density of submucosal lymphatics in this anatomical
462 region translates into these patients inherently performing worse – lending support to the robust
463 nature of our predictive signature. The notable absence of patritumab (denoted as ‘Drug’) in our
464 predictive signatures is also consistent with the outcome of the Phase 2 Clinical Trial where the
465 addition of this investigational medicinal product did not produce any benefit to PFS(8).

466 CD33+CD14+ monocytes demonstrated predictive capacity both as a univariate and as
467 a prominent feature in both baseline and combined signatures. Monocytes are a heterogenous
468 cell population, and phenotypic and functional characterization of monocyte subsets is a rapidly
469 emerging field(25). Our identified population of interest,
470 CD14+CD16+CD33+CD11b+CD11c+HLA-DR+ monocytes, resemble an intermediate
471 monocyte phenotype. This subset remains one of the most poorly characterized monocytic
472 subpopulations so far but have previously been linked to diverse immunological functions
473 including antigen processing and presentation, angiogenesis, and monocyte activation(26).
474 Interestingly, a significant correlation between the changes in miRNA-21-5p with changes in this
475 monocytic subpopulation was detected, supporting previous suggestions that miRNA signatures
476 can be a useful indicator of the functional state of myeloid cell subsets in cancer (20). The
477 predictive capacity of this subpopulation warrants investigation and further characterization in
478 future studies.

479 Beyond the interest in individual covariates, our study also reveals the potential of using
480 liquid-based biological outcomes to predict outcome to therapy. It has been widely recognized

481 that even the most utilized biomarkers, such as tumor PD-L1, have limited predictive value
482 when used in isolation. Our study reveals that a targeted multimodality signature, obtained
483 through longitudinal sampling of peripheral blood, is able to augment this predictive capacity
484 and better identify patients who would benefit from a particular treatment regimen.

485 There are a few limitations to the study. The absence of overall survival (OS) within our
486 current dataset represents one of the shortcomings of the study and it would have been
487 interesting to assess whether the immune markers, particularly the CD33+CD14+ monocytic
488 population, predict survival in the longer term. However, the accuracy of the predictive signature
489 for OS would have been diluted by a variety of subsequent treatment regimens. Secondly, due
490 to tissue scarcity, we only managed to obtain sufficient biopsy tissue from four patients for in-
491 depth profiling by mass cytometry to investigate the correlation of the monocytic population
492 between tissue and blood.

493 The present study shows that the combination of biomarkers established prospectively
494 by liquid biopsies early in the treatment course offers potential for the provision of personalized
495 treatments to patients (27). The post-stratification survival curves in our study demonstrate
496 markedly different progression free survivals as a testament to this robust statistical model, and
497 could represent an invaluable guide to clinicians during the initial stages of treatment.

498 FUNDING

499 This work was supported by a grant from Daiichi Sankyo Inc ('Identification of Non-
500 Invasive Treatment Stratification and Longitudinal Monitoring Markers for Patritumab/Cetuximab
501 Combination Therapy'). This work was also supported by Cancer Research UK funding support
502 to King's College London – UCL Comprehensive Cancer Imaging Centre (CR-UK & EPSRC),
503 Cancer Research UK King's Health Partners Centre at King's College London, and Cancer
504 Research UK UCL Centre; University College London (PRB) – Early Detection Award

505 (C7675/A29313); as well as CRUK City of London Centre. MG and KN are supported by Cancer
506 Research UK Clinical Training Fellowships (Award number 163011 for MG and 176885 for KN).
507 LD is supported by EU IMI2 IMMUCAN (Grant agreement number 821558). GA and JMV are
508 supported by CRUK Early Detection and Diagnosis Committee Project grant.

509 JWO is supported by the UK Medical Research Council (MR/N013700/1) and is a KCL
510 member of the MRC Doctoral Training Partnership in Biomedical Science. FW is also supported
511 by the UK Medical Research Council (MR/N013700/1). JNA is funded by a grant from the
512 European Research Council (335326).

513 MDF is supported by the UCL/UCLH NIHR Biomedical Research
514 Centre and runs early phase studies in the NIHR UCLH Clinical Research
515 Facility supported by the UCL ECMC. MTD and KH acknowledge funding support from The
516 Institute of Cancer Research/Royal Marsden Hospital NIHR Biomedical Research Centre.

517 This research was funded/supported by the National Institute for Health Research
518 (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and
519 King's College London and/or the NIHR Clinical Research Facility. The views expressed are
520 those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of
521 Health and Social Care.

522 **DATA AVAILABILITY STATEMENT**

523 The data generated in this study and used for multivariate modelling are available from the UCL
524 repository: <https://doi.org/10.5522/04/16566207.v1>

525 **NOTES**

526 **Affiliations of authors**

527 Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King's
528 College London, London, UK (FF-B,TN); Richard Dimbleby Laboratory of Cancer Research,
529 School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
530 (GA,GW,FW,RM,TN); Comprehensive Cancer Centre, School of Cancer & Pharmaceutical
531 Sciences, King's College London, London, UK (PRB); UCL Cancer Institute, Paul O'Gorman
532 Building, University College London, London, UK (PRB,JMV,MG,KN,JB,MDF,TN); Tumor
533 Immunology Group, School of Cancer & Pharmaceutical Sciences, King's College London,
534 London, UK (JWO, JNA), Systems Cancer Immunology, School of Cancer & Pharmaceutical
535 Sciences, King's College London, London, UK (SK), Daiichi Sankyo Incorporated, New Jersey,
536 USA (JD,JG); The Institute of Cancer Research/The Royal Marsden Hospital National Institute
537 for Health Research Biomedical Research Centre, London, UK (KH, MTD); Institute for
538 Mathematical and Molecular Biomedicine, King's College London, UK (ACC), Saddle Point
539 Science Ltd, London, UK (ACC), Centre for Immunobiology and Regenerative Medicine, Barts &
540 The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
541 (Current Affiliation for FF-B) ; Barts Health NHS Trust, London, UK (Current Affiliation for MG).

542 **Conflict of Interests**

543 KN has received honoraria from Pfizer, GSK/Tesaro and Boehringer Ingelheim, and has
544 had travel/accommodation/expenses paid for by Tesaro. MDF has received institutional
545 research funding from AstraZeneca, Boehringer-Ingelheim, Merck and MSD and serves in a
546 consulting or advisory role to Achilles, Astrazeneca, Bayer, Bristol-Myers Squibb, Celgene,
547 Guardant Health, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pfizer, Roche, Takeda,
548 UltraHuman. KH has received honoraria from Amgen; Arch Oncology; AstraZeneca;
549 Boehringer-Ingelheim; Bristol-Myers Squibb; Codiak; Inzen; Merck; MSD; Pfizer; Replimune and
550 is on a speakers' bureau for Amgen, AstraZeneca; Bristol-Myers Squibb; Merck, MSD; Pfizer.

551 KH has also received research funding from AstraZeneca, Boehringer-Ingelheim, MSD and
552 Replimune.

553 JG and JD are both in employment with Daiichi Sankyo, and have stock and other
554 ownership interests, research funding within Daichii Sanyko and have had
555 travel/accommodation/expenses paid for by Daichii Sankyo. In addition, JD has also had stock
556 and other ownership interests with Pfizer and received research funding from Novartis. ACCC
557 has stock and other ownership interests with Saddle Point Science Limited.

558 FW was initially funded by Daichii Sankyo as research assistant to conduct laboratory
559 work in the context of the translational aspect of this trial. SK has received research funding in
560 the form of a grant from Novartis and Celgene. TN has received research funding from
561 Astrazeneca and Daichii Saky. TN is a founder and shareholder in Nano Clinical Ltd, and PRB
562 is a shareholder.

563 FF-B,GA, GW,JMV,MG,JWO,JB and RM declare no conflicts of interests.

564 The funders had no role in the study design, the collection, analysis and interpretation of the
565 data, the writing of the manuscript, and the decision to publish.

566 **ETHICS AND PERMISSIONS**

567 Written informed consent was obtained for all patients who participated in the Phase 2 clinical
568 trial. Approval was obtained from ethics committees (Research Ethics Committee reference:
569 15/LO/1670). Approval to procure and process a separate cohort of blood samples from patients
570 at risk of developing lung cancer was also obtained (IRAS ID: 261766).

571 **ACKNOWLEDGEMENTS**

572 We thank the patients who participated in this Phase 2 trial and the staff members at the study
573 sites who cared for them. We also thank Dr James Barrett for his assistance towards designing
574 the statistical techniques applied in this study.

575 **PRIOR PRESENTATIONS**

576 This study was presented at the 2018 American Society of Clinical Oncology (ASCO) Annual
577 Meeting in Chicago, June 1-5, 2018.

578 **LIST OF SUPPLEMENTARY MATERIALS**

579 Supplementary Figure 1: Kaplan Meier Curve of Progression Free Survival in Study Cohort

580 Supplementary Table 1: Demographic and Laboratory-Based Values of Patients Within Study

581 Supplementary Table 2: List of covariates entered into Bayesian Multivariate Analysis

582

583 Supplementary Table 3: Demographic and Laboratory-Based Values of Patients Separated by

584 Arm of Treatment Within Trial

585 Supplementary Figure 2: Gating Strategies For Definition of Peripheral Blood Immune

586 Populations

587 Supplementary Table 4: List of antibodies used in T cell panel and B cell-Monocyte Panel for

588 Flow Cytometry

589 Supplementary Table 5: List of Antibodies Used in Imaging Mass Cytometry (CyTOF) Analysis

590 for Definition of Immune Subpopulations

591 Supplementary Table 6: List of populations in imaging mass cytometry of tissue and

592 corresponding signature

593 Supplementary Figure 3: Gating strategy for further characterization of CD33+CD14+ monocytic


594 population using new patient cohort

595 REFERENCES

- 596 1. Burtneß B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., et al. Pembrolizumab alone or
597 with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the
598 head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet*. 2019;394(10212):1915-28.
- 599 2. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and
600 chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med*. 2009;360(14):1408-17.
- 601 3. Bossi P, Bergamini C, Siano M, Cossu Rocca M, Sponghini AP, Favales F, et al. Functional Genomics
602 Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.
603 *Clin Cancer Res*. 2016;22(15):3961-70.
- 604 4. You GR, Cheng AJ, Lee LY, Huang YC, Liu H, Chen YJ, et al. Prognostic signature associated with
605 radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses. *BMC Cancer*. 2019;19(1):64.
- 606 5. Cheerla A, Gevaert O. Deep learning with multimodal representation for pancancer prognosis prediction.
607 *Bioinformatics*. 2019;35(14):i446-i54.
- 608 6. Huang Z, Zhan X, Xiang S, Johnson TS, Helm B, Yu CY, et al. SALMON: Survival Analysis Learning
609 With Multi-Omics Neural Networks on Breast Cancer. *Front Genet*. 2019;10:166.
- 610 7. Tseng YJ, Wang HY, Lin TW, Lu JJ, Hsieh CH, Liao CT. Development of a Machine Learning Model for
611 Survival Risk Stratification of Patients With Advanced Oral Cancer. *JAMA Netw Open*. 2020;3(8):e2011768.
- 612 8. Forster MD, Dillon MT, Kocsis J, Remenar E, Pajkos G, Rolland F, et al. Patritumab or placebo, with
613 cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A
614 randomised phase II study. *Eur J Cancer*. 2019;123:36-47.
- 615 9. Summerer I, Unger K, Braselmann H, Schuettrumpf L, Maihoefer C, Baumeister P, et al. Circulating
616 microRNAs as prognostic therapy biomarkers in head and neck cancer patients. *Br J Cancer*. 2015;113(1):76-82.
- 617 10. Vahabi MBG, Di Agostino, S. MicroRNAs in head and neck squamous cell carcinoma: a possible
618 challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies.
619 *Transl Cancer Res*. 2021;10(6):3090-110.
- 620 11. Grigoriadis A, Gazinska P, Pai T, Irhsad S, Wu Y, Millis R, et al. Histological scoring of immune and
621 stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast
622 cancers. *J Pathol Clin Res*. 2018;4(1):39-54.
- 623 12. Harrell FE, Jr., Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved
624 prognostic prediction. *Stat Med*. 1984;3(2):143-52.
- 625 13. Barber PR, Weitsman G, Lawler K, Barrett JE, Rowley M, Rodriguez-Justo M, et al. HER2-HER3
626 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. *J Natl*
627 *Cancer Inst*. 2020;112(9):944-54.
- 628 14. Shalabi A, Inoue M, Watkins J, De Rinaldis E, Coolen AC. Bayesian clinical classification from high-
629 dimensional data: Signatures versus variability. *Stat Methods Med Res*. 2018;27(2):336-51.
- 630 15. Monypenny J, Milewicz H, Flores-Borja F, Weitsman G, Cheung A, Chowdhury R, et al. ALIX Regulates
631 Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation. *Cell Rep*.
632 2018;24(3):630-41.
- 633 16. Barber PR, Tullis ID, Pierce GP, Newman RG, Prentice J, Rowley MI, et al. The Gray Institute 'open' high-
634 content, fluorescence lifetime microscopes. *J Microsc*. 2013;251(2):154-67.
- 635 17. Barber PR, Ameer-Beg SM, Gilbey J, Carlin LM, Keppler M, Ng TC, et al. Multiphoton time-domain
636 FLIM: Practical application to protein-protein interactions using global analysis. *J R Soc Interface*. 2009;6:S93-
637 S105.
- 638 18. Rowley MI, Coolen ACC, Vojnovic B, Barber PR. Robust Bayesian Fluorescence Lifetime Estimation,
639 Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging. *PLOS ONE*.
640 2016;11(6):e0158404.
- 641 19. Cravens PD, Hayashida K, Davis LS, Nanki T, Lipsky PE. Human peripheral blood dendritic cells and
642 monocyte subsets display similar chemokine receptor expression profiles with differential migratory responses.
643 *Scand J Immunol*. 2007;65(6):514-24.
- 644 20. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-
645 derived suppressor cell nomenclature and characterization standards. *Nat Commun*. 2016;7:12150.

- 646 21. Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang IM, Fleener C. Peripheral immune-based biomarkers in
647 cancer immunotherapy: can we realize their predictive potential? *J Immunother Cancer*. 2019;7(1):325.
648 22. Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised
649 treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. *Lancet Oncol*.
650 2017;18(8):1022-39.
651 23. Machiels JP, Rene Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V, et al. Squamous cell
652 carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice
653 Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2020;31(11):1462-75.
654 24. Cadoni G, Giraldi L, Petrelli L, Pandolfini M, Giuliani M, Paludetti G, et al. Prognostic factors in head and
655 neck cancer: a 10-year retrospective analysis in a single-institution in Italy. *Acta Otorhinolaryngol Ital*.
656 2017;37(6):458-66.
657 25. Ginhoux F, Mildner A, Gautier EL, Schlitzer A, Jakubzick C, Varol C, et al. Editorial: Monocyte
658 Heterogeneity and Function. *Front Immunol*. 2020;11:626725.
659 26. Zawada AM, Rogacev KS, Rotter B, Winter P, Marell RR, Fliser D, et al. SuperSAGE evidence for
660 CD14⁺⁺CD16⁺ monocytes as a third monocyte subset. *Blood*. 2011;118(12):e50-61.
661 27. Nenclares P, Gunn L, Soliman H, Bover M, Trinh A, Leslie I, et al. On-treatment immune prognostic score
662 for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. *J*
663 *Immunother Cancer*. 2021;9(6).

665



Supplementary Figure 1. Kaplan Meier Curve of Progression-Free Survival in Study Cohort

Progression-Free Survival data was obtained from 53 patients, and stratified according to patients who received patritumab and the cohort which received placebo.

	Overall
Age (mean (SD))	58.46 (8.78)
Drug = Placebo (%)	27 (48.2)
Sex = M (%)	46 (82.1)
Site (%)	
Aryepiglottis	1 (1.8)
Hypopharynx	12 (21.4)
Larynx	8 (14.3)
Oral Cavity	20 (35.7)
Oropharynx	10 (17.9)
Other	5 (8.9)
Prev.Cetux = Yes (%)	1 (1.8)
HPV.Status = Pos (%)	8 (14.3)
Hereg.Status = Low (%)	27 (48.2)
Smoking (%)	
Current	18 (32.1)
Ex	34 (60.7)
Never	3 (5.4)
Other	1 (1.8)
Dendritic.CD33.c1 (mean (SD))	4.49 (4.46)
T.cell.CD3.c1 (mean (SD))	44.74 (20.79)
T.cell.CD4.c1 (mean (SD))	50.07 (18.43)
T.cell.CD4.Cent.Mem.c1 (mean (SD))	27.99 (9.58)
T.cell.CD4.Effector.c1 (mean (SD))	9.15 (18.07)
T.cell.CD4.Effect.Mem.c1 (mean (SD))	31.77 (17.04)
CD4.Naive.c1 (mean (SD))	30.07 (20.86)
CD4.Tregs.c1 (mean (SD))	8.97 (5.24)
CD4.Memory.Tregs.c1 (mean (SD))	62.15 (12.50)
CD4.Mem.Act.Tregs.c1 (mean (SD))	22.45 (12.25)
CD4.Naive.Tregs.c1 (mean (SD))	14.69 (14.08)
T.cell.CD8.c1 (mean (SD))	35.27 (12.98)
CD8.Cent.Mem.c1 (mean (SD))	9.34 (4.87)
CD8.Effector.c1 (mean (SD))	38.74 (15.99)
CD8.Effect.Mem.c1 (mean (SD))	33.38 (12.13)
CD8.Naive.c1 (mean (SD))	18.54 (13.92)
CD4.CD8.ratio.c1 (mean (SD))	1.85 (1.23)
B.cell.CD19..c1 (mean (SD))	17.15 (8.62)
B.cell.mature.c1 (mean (SD))	58.50 (13.45)
B.cell.memory.c1 (mean (SD))	21.18 (12.04)
B.cell.Transitional.c1 (mean (SD))	7.30 (8.30)
B.cell.plasma.c1 (mean (SD))	0.36 (0.62)
B.cell.DN.c1 (mean (SD))	13.84 (9.01)
B.cell.naive.c1 (mean (SD))	68.07 (14.55)
B.cell.pre.switch.c1 (mean (SD))	4.82 (5.52)
B.cell.post.switch.c1 (mean (SD))	13.26 (8.83)
FRET.c1 (mean (SD))	0.00 (0.05)
normalised.miR.21.5.c1 (mean (SD))	0.00 (0.01)
normalised.miR.142.3p.c1 (mean (SD))	0.00 (0.00)
FRET.c1.missing (mean (SD))	0.14 (0.35)
miR.c1.missing (mean (SD))	0.11 (0.31)
immune.c1.missing (mean (SD))	0.38 (0.49)
Dendritic.CD33.lfc (mean (SD))	0.31 (1.29)
T.cell.CD3.lfc (mean (SD))	0.28 (0.57)
T.cell.CD4.lfc (mean (SD))	0.12 (0.63)
T.cell.CD4.Cent.Mem.lfc (mean (SD))	0.01 (0.62)
T.cell.CD4.Effector.lfc (mean (SD))	-0.37 (1.00)
T.cell.CD4.Effect.Mem.lfc (mean (SD))	0.01 (0.84)
CD4.Naive.lfc (mean (SD))	0.08 (0.98)
CD4.Tregs.lfc (mean (SD))	-0.21 (0.72)
CD4.Memory.Tregs.lfc (mean (SD))	-0.02 (0.30)
CD4.Mem.Act.Tregs.lfc (mean (SD))	0.19 (0.77)
CD4.Naive.Tregs.lfc (mean (SD))	-0.10 (0.97)
T.cell.CD8.lfc (mean (SD))	0.11 (0.41)
CD8.Cent.Mem.lfc (mean (SD))	0.12 (0.74)
CD8.Effector.lfc (mean (SD))	-0.17 (0.62)
CD8.Effect.Mem.lfc (mean (SD))	0.03 (0.33)
CD8.Naive.lfc (mean (SD))	-0.15 (0.85)
CD4.CD8.ratio.lfc (mean (SD))	-0.12 (0.79)
B.cell.CD19..lfc (mean (SD))	-0.07 (0.89)
B.cell.mature.lfc (mean (SD))	0.03 (0.45)
B.cell.memory.lfc (mean (SD))	0.10 (0.45)
B.cell.Transitional.lfc (mean (SD))	-0.26 (0.77)
B.cell.plasma.lfc (mean (SD))	0.12 (2.03)
B.cell.DN.lfc (mean (SD))	-0.18 (0.61)
B.cell.naive.lfc (mean (SD))	-0.01 (0.21)
B.cell.pre.switch.lfc (mean (SD))	0.14 (0.66)
B.cell.post.switch.lfc (mean (SD))	0.01 (0.62)
normalised.miR.21.5.lfc (mean (SD))	0.25 (2.12)
normalised.miR.142.3p.lfc (mean (SD))	0.13 (1.98)
FRET.delta (mean (SD))	0.00 (0.05)
FRET.delta.missing (mean (SD))	0.18 (0.39)
miR.lfc.missing (mean (SD))	0.11 (0.31)
immune.lfc.missing (mean (SD))	0.46 (0.50)
BOR.RECIST (mean (SD))	2.74 (0.68)
event.PFS (mean (SD))	0.74 (0.45)
t.PFS (mean (SD))	5.48 (3.48)

Supplementary Table 1. Demographic and Laboratory-Based Values of patients Group of 56

patients with HNSCC was analyzed and their characteristics indicated as above.


Lab-Based Covariates (n=58) CC-BY 4.0 International license				Baseline Clinical Covariates (n=13)
PBMC-Based		Exosome-Based		
Panel A	Panel B	FRET value	miRNA	
CD3 T cells	CD19 B cells	FRET-FLIM	miR 21.5	Patritumab (Drug) Age Sex Smoking Status Site: -Oral Cavity -Oropharynx -Hypopharynx -Aryepiglottis -Larynx -Other Previous Cetuximab HPV Status: +ve/-ve Heregulin Status
CD4 T cells	Mature B cells	EGFR-ErbB3	miR 142.3p	
CD8 T cells	Transitional B cells			
CD4 Central Memory	Plasma B cells			
CD4 Effector Memory	Double Negative B cells			
CD4 Naïve	Naïve B cells			
CD4 Tregs	Pre switch B cells			
CD4 Memory Tregs	Post switch B cells			
CD4 Mem Act Tregs	CD33+CD14+ Monocytes			
CD4 Naïve Tregs				
CD8 Central Memory				
CD8 Effector Memory				
CD8 Naïve				
CD4.CD8 ratio				

Supplementary Table 2: List of covariates entered into Bayesian multivariate analysis. 29 laboratory-based covariates were used (obtained at baseline and after one cycle of treatment), and combined with 13 baseline clinical covariates.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	Patritumab	Placebo	p
Age (mean (SD))	58.17 (8.59)	58.78 (9.14)	0.799
Drug = Placebo (%)	0 (0.0)	27 (100.0)	<0.001
Sex = M (%)	22 (75.9)	24 (88.9)	0.356
Site (%)			0.498
Aryepiglottis	1 (3.4)	0 (0.0)	
Hypopharynx	7 (24.1)	5 (18.5)	
Larynx	3 (10.3)	5 (18.5)	
Oral Cavity	12 (41.4)	8 (29.6)	
Oropharynx	3 (10.3)	7 (25.9)	
Other	3 (10.3)	2 (7.4)	
Prev.Cetux = Yes (%)	0 (0.0)	1 (3.7)	0.971
HPV.Status = Pos (%)	4 (13.8)	4 (14.8)	1
Hereg.Status = Low (%)	14 (48.3)	13 (48.1)	1
Smoking (%)			0.36
Current	7 (24.1)	11 (40.7)	
Ex	20 (69.0)	14 (51.9)	
Never	1 (3.4)	2 (7.4)	
Other	1 (3.4)	0 (0.0)	
Dendritic.CD33.c1 (mean (SD))	4.17 (4.71)	4.73 (4.38)	0.716
T.cell.CD3.c1 (mean (SD))	45.64 (21.50)	44.08 (20.82)	0.836
T.cell.CD4.c1 (mean (SD))	49.68 (17.43)	50.36 (19.60)	0.919
T.cell.CD4.Cent.Mem.c1 (mean (SD))	29.86 (10.13)	26.61 (9.18)	0.343
T.cell.CD4.Effector.c1 (mean (SD))	17.41 (25.54)	3.07 (4.19)	0.022
T.cell.CD4.Effect.Mem.c1 (mean (SD))	31.04 (17.90)	32.32 (16.85)	0.834
CD4.Naive.c1 (mean (SD))	21.39 (16.57)	36.46 (21.76)	0.038
CD4.Tregs.c1 (mean (SD))	8.79 (4.05)	9.11 (6.07)	0.864
CD4.Memory.Tregs.c1 (mean (SD))	60.04 (14.54)	63.69 (10.91)	0.415
CD4.Mem.Act.Tregs.c1 (mean (SD))	20.58 (11.36)	23.83 (12.99)	0.46
CD4.Naive.Tregs.c1 (mean (SD))	18.84 (19.33)	11.62 (7.69)	0.148
T.cell.CD8.c1 (mean (SD))	37.41 (13.69)	33.64 (12.59)	0.44
CD8.Cent.Mem.c1 (mean (SD))	8.83 (3.60)	9.74 (5.73)	0.619
CD8.Effector.c1 (mean (SD))	42.45 (18.41)	35.90 (13.76)	0.273
CD8.Effect.Mem.c1 (mean (SD))	30.91 (15.34)	35.26 (9.02)	0.338
CD8.Naive.c1 (mean (SD))	17.81 (13.23)	19.10 (14.80)	0.807
CD4.CD8.ratio.c1 (mean (SD))	1.83 (1.42)	1.88 (1.11)	0.913
B.cell.CD19.c1 (mean (SD))	16.69 (8.88)	17.50 (8.63)	0.789
B.cell.mature.c1 (mean (SD))	55.65 (16.19)	60.64 (10.92)	0.284
B.cell.memory.c1 (mean (SD))	22.00 (15.59)	20.56 (8.90)	0.731
B.cell.Transitional.c1 (mean (SD))	8.55 (12.20)	6.37 (3.37)	0.448
B.cell.plasma.c1 (mean (SD))	0.27 (0.30)	0.42 (0.77)	0.467
B.cell.DN.c1 (mean (SD))	12.40 (7.87)	14.92 (9.83)	0.421
B.cell.naive.c1 (mean (SD))	70.15 (15.33)	66.51 (14.13)	0.472
B.cell.pre.switch.c1 (mean (SD))	5.71 (7.51)	4.16 (3.46)	0.421
B.cell.post.switch.c1 (mean (SD))	11.73 (8.45)	14.40 (9.14)	0.384
FRET.c1 (mean (SD))	-0.01 (0.05)	0.00 (0.06)	0.679
normalised.miR.21.5.c1 (mean (SD))	0.00 (0.00)	0.01 (0.02)	0.531
normalised.miR.142.3p.c1 (mean (SD))	0.00 (0.00)	0.00 (0.00)	0.687
FRET.c1.missing (mean (SD))	0.07 (0.26)	0.22 (0.42)	0.105
miR.c1.missing (mean (SD))	0.10 (0.31)	0.11 (0.32)	0.928
immune.c1.missing (mean (SD))	0.48 (0.51)	0.26 (0.45)	0.087
Dendritic.CD33.lfc (mean (SD))	0.14 (1.02)	0.42 (1.47)	0.569
T.cell.CD3.lfc (mean (SD))	0.25 (0.61)	0.30 (0.56)	0.833
T.cell.CD4.lfc (mean (SD))	0.08 (0.54)	0.15 (0.70)	0.796
T.cell.CD4.Cent.Mem.lfc (mean (SD))	-0.27 (0.70)	0.20 (0.48)	0.038
T.cell.CD4.Effector.lfc (mean (SD))	-0.53 (0.96)	-0.25 (1.03)	0.459
T.cell.CD4.Effect.Mem.lfc (mean (SD))	-0.02 (0.86)	0.04 (0.86)	0.855
CD4.Naive.lfc (mean (SD))	0.19 (1.07)	0.01 (0.94)	0.639
CD4.Tregs.lfc (mean (SD))	-0.23 (0.91)	-0.19 (0.58)	0.891
CD4.Memory.Tregs.lfc (mean (SD))	-0.14 (0.35)	0.06 (0.25)	0.086
CD4.Mem.Act.Tregs.lfc (mean (SD))	0.39 (0.83)	0.06 (0.71)	0.255
CD4.Naive.Tregs.lfc (mean (SD))	-0.28 (0.76)	0.02 (1.08)	0.432
T.cell.CD8.lfc (mean (SD))	0.14 (0.38)	0.09 (0.44)	0.756
CD8.Cent.Mem.lfc (mean (SD))	0.05 (0.59)	0.17 (0.85)	0.698
CD8.Effector.lfc (mean (SD))	-0.34 (0.64)	-0.06 (0.60)	0.263
CD8.Effect.Mem.lfc (mean (SD))	0.15 (0.33)	-0.05 (0.31)	0.125
CD8.Naive.lfc (mean (SD))	0.02 (0.56)	-0.27 (1.00)	0.39
CD4.CD8.ratio.lfc (mean (SD))	-0.19 (0.66)	-0.08 (0.89)	0.734
B.cell.CD19.lfc (mean (SD))	0.00 (1.06)	-0.12 (0.78)	0.707
B.cell.mature.lfc (mean (SD))	0.21 (0.38)	-0.08 (0.46)	0.078
B.cell.memory.lfc (mean (SD))	0.01 (0.46)	0.15 (0.45)	0.411
B.cell.Transitional.lfc (mean (SD))	-0.21 (0.74)	-0.29 (0.80)	0.775
B.cell.plasma.lfc (mean (SD))	0.43 (1.97)	-0.04 (2.10)	0.564
B.cell.DN.lfc (mean (SD))	-0.43 (0.68)	-0.02 (0.52)	0.066
B.cell.naive.lfc (mean (SD))	0.06 (0.23)	-0.06 (0.19)	0.126
B.cell.pre.switch.lfc (mean (SD))	0.19 (0.82)	0.10 (0.56)	0.729
B.cell.post.switch.lfc (mean (SD))	-0.09 (0.57)	0.08 (0.65)	0.459
normalised.miR.21.5.lfc (mean (SD))	0.34 (2.13)	0.13 (2.16)	0.734
normalised.miR.142.3p.lfc (mean (SD))	0.51 (1.93)	-0.28 (1.99)	0.161
FRET.delta (mean (SD))	0.00 (0.05)	0.00 (0.05)	0.631
FRET.delta.missing (mean (SD))	0.14 (0.35)	0.22 (0.42)	0.42
miR.lfc.missing (mean (SD))	0.10 (0.31)	0.11 (0.32)	0.928
immune.lfc.missing (mean (SD))	0.59 (0.50)	0.33 (0.48)	0.06
BOR.RECIST (mean (SD))	2.64 (0.68)	2.85 (0.67)	0.275
event.PFS (mean (SD))	0.71 (0.46)	0.76 (0.44)	0.713
t.PFS (mean (SD))	4.94 (2.83)	6.08 (4.06)	0.237

Supplementary Table 3. Demographic and Laboratory-Based Values of patients separated by arm of treatment on trial (placebo vs patritumab)



Supplementary Figure 2. Gating strategies for definition of peripheral blood immune populations. Peripheral immune cell populations analysed in this study are indicated in corresponding gates

A) Subpopulations of CD3⁺ CD4⁺ and CD3⁺ CD8⁺ T cells were further identified by the use of markers CCR7 and CD45RO as effector (Eff., CD45RO⁻ CCR7⁻), naïve (CD45RO⁻ CCR7⁺), central memory (CM, CD45RO⁺ CCR7⁺) and effector memory (EM, CD45RO⁺ CCR7⁻). The activation status of CD4⁺ regulatory T cells (Tregs, CD127^{-/lo} CD25^{hi}) was defined by markers CD45RO and HLA-DR as indicated: naïve Tregs (HLA-DR⁻ CD45RO⁻), activated Tregs (Act. Tregs, HLA-DR⁺ CD45RO⁺), and memory Tregs (Mem. Tregs, HLA-DR⁻ CD45RO⁺). **B)** CD19⁺ B cell subpopulations were identified with markers CD24, CD38 and CD27: plasma cells (CD38⁺ CD27⁺); mature (CD24^{lo} CD38^{lo}), memory (CD24^{hi} CD38^{hi}), transitional (TBC, CD24^{hi} CD38^{hi}); or a combination of IgD and CD27: naïve (IgD⁺ CD27⁻), memory pre-switch (IgD⁺ CD27⁺), memory post-switch (IgD⁻ CD27⁺),

or double-negative B cells (DN, IgD⁻CD27⁻). CD33⁺CD14⁺ Monocytes were defined as CD3⁻CD19⁻CD33⁺CD16⁺CD14⁺.

T cell Panel			B cell-Monocyte Panel		
Target	Clone	Company	Target	Clone	Company
CD3	UCHT1	BD Biosciences	CD3	UCHT1	BD Biosciences
CD4	SK3	BD Biosciences	CD11b	ICRF44	Biolegend
CD8	RPA-T8	BD Biosciences	CD14	HCD14	Biolegend
CD25	M-A251	BD Biosciences	CD16	3G8	BD Biosciences
CD45RO	UCHL1	BD Biosciences	CD19	HIB19	Biolegend
CD127	HIL-7R-M21	BD Biosciences	CD24	ML5	Biolegend
CCR7	GO43H7	Biolegend	CD27	LI28	Biolegend
HLA-DR	G46-6	BD Biosciences	CD33	P67.6	Biolegend
			CD38	HB7	Biolegend
			IgD	IA6.2	Biolegend

Supplementary Table 4 List of antibodies used in T cell panel and B cell-monocyte panel for analyses of immune cell populations by flow cytometry. Antibodies were purchased from BD Biosciences and Biolegend as indicated.


Channel	Target	CLONE	Company	Code	Custom Conjugation
142Nd	SMA	1A4	Fluidigm	3141017D	No
144Nd	CD14	EPR3653	Fluidigm	3144025D	No
149Sm	CD11b	EPR1344	Fluidigm	3149028D	No
150Nd	CD15	W6D3	Fluidigm	3149026D	No
151Eu	IgD	IgD26	NovusBio	NBP2-50437	Yes
153Eu	CD24	ALB9	abcam	ab31622	Yes

154Sm	CD11c	EP1347Y	Fluidigm	3159035D	Yes
160Gd	CD68	KP1	Fluidigm	3159035D	No
164Dy	ARGINASE-1	D4E3M	Fluidigm	3164027D	No
165Ho	CD45RA	HI100	BioLegend	304102	Yes
166Er	CD74	LN2	Fluidigm	3166025D	No
175Lu	CD25	EPR6452	Fluidigm	3175036D	No
141Pr	CD38	EPR4106	Fluidigm	3141018D	No
143Nd	VIMENTIN	RV202	Fluidigm	3143029D	No
145Nd	CD33	POLY	Fluidigm	3145017D	No
146Nd	CD16	EPR16784	Fluidigm	3146020D	No
148Nd	Pan-Keratin	C11	Fluidigm	3148020D	No
152Sm	CD45	CD45-2B11	Fluidigm	3152016D	No
155Gd	FOXP3	236A/E7	Fluidigm	3155016D	No
156Gd	CD4	EPR6855	Fluidigm	3156033D	No
158Gd	E-CAD	24 E10	Fluidigm	3158029D	No
161Dy	CD20	H1	Fluidigm	3161029D	No
162Dy	CD8a	D8A8Y	Fluidigm	3162035D	No
168Er	CD127	EPR2955(2)	Fluidigm	3168026D	No
169Tm	COLLAGEN-I	POLY	Fluidigm	3169023D	No
170Er	CD3	POLY	Fluidigm	3170019D	No
171Yb	CD27	EPR8569	Fluidigm	3171024D	No
173Yb	CD45RO	UCHL1	Fluidigm	3173016D	No

Supplementary Table 5 List of antibodies used in mass cytometry (CyToF) analyses for definition of immune cell subpopulations in tissue.

Pixel-level	Cell-level	Signature	Populations
A	0	e-Cadherin ⁺ / Pan-Keratinin ^{+/±} / Vimentin ⁻	Epithelium/ tumor
B	26	CD11b ^{int} / CD33 ^{neg} / CD14 ^{int} / CD15 ^{neg} / CD68 ^{hi} / CD11c ^{int} / CD74 ^{hi}	Macrophages CD74 ^{hi}
	37	CD11b ^{int} / CD33 ^{pos} / CD14 ^{hi} / CD15 ^{neg} / CD68 ^{int} / CD11c ^{int} / CD74 ^{int}	CD33+ CD14+ Monocytes
	48	CD11b ^{int} / CD33 ^{neg} / CD14 ^{hi} / CD15 ^{neg} / CD68 ^{hi} / CD11c ^{int} / CD74 ^{int}	Mono/ Macro
	60	CD11b ^{int} / CD33 ^{pos} / CD14 ^{hi} / CD15 ^{neg} / CD68 ^{neg} / CD11c ^{neg} / CD74 ^{int}	MO-MDSC
	61	CD11b ^{int} / CD33 ^{neg} / CD14 ^{int} / CD15 ^{neg} / CD68 ^{neg} / CD11c ^{neg} / CD74 ^{int}	ILC-1
	64	CD11b ^{hi} / CD33 ^{neg} / CD14 ^{int} / CD15 ^{hi} / CD68 ^{int} / CD11c ^{neg} / CD74 ^{neg}	G-MDSC
	9	CD11b ^{int} / CD33 ^{pos} / CD14 ^{int} / CD15 ^{neg} / CD68 ^{neg} / CD11c ^{neg} / CD74 ^{neg}	Monocyte
	0	---	Myeloid
C	0	SMA ⁺	Fibroblast
D	33	CD3 ^{hi} / CD8 ^{hi} / CD27 ^{neg} / CD45RA ^{neg} / CD45RO ^{int} / CD127 ^{neg}	CD8 ⁺ Effector
	41	CD3 ^{hi} / CD8 ^{hi} / CD27 ^{int} / CD45RA ^{hi} / CD45RO ^{int}	CD8 ⁺ Central memory
	42	CD3 ^{hi} / CD8 ^{hi} / CD27 ^{neg} / CD45RA ^{neg} / CD45RO ^{hi}	CD8 ⁺ Effector memory
	0	---	CD8 ⁺ T-Cells
E	28	CD3 ^{low} / CD4 ^{hi} / CD27 ^{neg} / CD45RA ^{neg} / CD45RO ^{int} / foxP3 ^{neg} / CD25 ^{neg} / CD127 ^{int} / CD74 ^{hi}	CD4 ⁺ Effector memory
	34	CD3 ^{hi} / CD4 ^{hi} / CD27 ^{neg} / CD45RA ^{neg} / CD45RO ^{hi} / foxP3 ^{neg} / CD25 ^{neg} / CD127 ^{int} / CD74 ^{int}	CD4 ⁺ Effector memory
	49	CD3 ^{hi} / CD4 ^{hi} / CD27 ^{neg} / CD45RA ^{neg} / CD45RO ^{int} / foxP3 ^{neg} / CD25 ^{neg} / CD127 ^{low} / CD74 ^{int}	CD4 ⁺ Central memory
	50	CD3 ^{hi} / CD4 ^{hi} / CD27 ^{int} / CD45RA ^{neg} / CD45RO ^{int} / foxP3 ^{int} / CD25 ^{low} / CD127 ^{low} / CD74 ^{int}	CD4 ⁺ activated
	51	CD3 ^{hi} / CD4 ^{hi} / CD27 ^{hi} / CD45RA ^{hi} / CD45RO ^{int} / foxP3 ^{neg} / CD25 ^{low} / CD127 ^{int} / CD74 ^{int}	CD4 ⁺ Naïve
	57	CD3 ^{hi} / CD4 ^{hi} / CD27 ^{int} / CD45RA ^{neg} / CD45RO ^{int} / foxP3 ^{hi} / CD25 ^{int} / CD127 ^{low} / CD74 ^{int}	T-reg CD45RO+
	58	CD3 ^{hi} / CD4 ^{hi} / CD27 ^{int} / CD45RA ^{int} / CD45RO ^{int} / foxP3 ^{neg} / CD25 ^{low} / CD127 ^{int} / CD74 ^{int}	CD4 ⁺ Effector
	0	---	CD4 ⁺ T-Cells
F	59	CD3 ^{neg} / CD20 ^{hi}	B-Cell
	0	---	B-Cell

Supplementary Table 6 List of populations in imaging mass cytometry of tissue and corresponding signature. ILC = Innate Lymphoid Cells, T-reg = Regulatory T cells, SMA = Smooth Muscle Actin, MO-MDSC = Monocytic Myeloid Derived Suppressor Cells, G-MDSC = Granulocytic Myeloid Derived Suppressor Cells



Supplementary Figure 3 Gating strategy for further characterisation of CD33+CD14+

monocytic population using new patient cohort CD14+CD16lowCD33+CD11b monocytes also express high levels of HLADR and CD11c.

Baseline Risk Score	Combined Risk Score
$S = (-0.278426819992) * \text{MDSC.of.CD33..c1}$	$S = (1.615133865474) * \text{Site.Hypopharynx}$
$+ (-0.060298841476) * \text{B.cell.DN.c1}$	$+ (-0.224319089905) * \text{MDSC.of.CD33..c1}$
$+ (0.053313459288) * \text{Age}$	$+ (-0.057227235933) * \text{CD4.Memory.Tregs.c1}$
$- (1.142256112742)$	$+ (0.561268824195) * \text{T.cell.CD3.lfc}$
	$+ (1.290959733907) * \text{CD8.Cent.Mem.lfc}$
	$+ (-1.498015339199) * \text{CD8.Effect.Mem.lfc}$
	$- (-3.790127113280)$

Supplementary Figure 4 Risk score signatures for use with raw covariate values, with missing data imputed with the study mean from Supplementary Table 1. Use these equations to calculate the risk score for each patient.